Adjuvant EGFR TKIs in NSCLC harboring EGFR mutations: looking for a consensus way.
作者信息
Attili Ilaria, Passaro Antonio, Spaggiari Lorenzo, Spitaleri Gianluca, de Marinis Filippo
机构信息
Division of Thoracic Oncology, IEO, European Institute of Oncology IRCCS, Milan, Italy.
Department of Surgery, Oncology and Gastroenterology, Faculty of Medicine, University of Padua, Padua, Italy.
出版信息
Ann Transl Med. 2020 Sep;8(17):1111. doi: 10.21037/atm.2020.04.35.
Abstract
摘要
相似文献
1
Adjuvant EGFR TKIs in NSCLC harboring EGFR mutations: looking for a consensus way.
Ann Transl Med. 2020 Sep;8(17):1111. doi: 10.21037/atm.2020.04.35.
2
EGFR inhibitors as adjuvant therapy for resected non-small cell lung cancer harboring EGFR mutations.
Lung Cancer. 2019 Oct;136:6-14. doi: 10.1016/j.lungcan.2019.08.001. Epub 2019 Aug 2.
3
A meta-analysis of adjuvant EGFR-TKIs for patients with resected non-small cell lung cancer.
Lung Cancer. 2019 Nov;137:7-13. doi: 10.1016/j.lungcan.2019.08.002. Epub 2019 Aug 5.
4
Outcomes of adjuvant epithelial growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) treatment for EGFR-mutant non-small-cell lung cancer: a propensity-score analysis.
Sci Rep. 2017 Sep 14;7(1):11528. doi: 10.1038/s41598-017-11725-9.
5
Next-generation EGFR/HER tyrosine kinase inhibitors for the treatment of patients with non-small-cell lung cancer harboring EGFR mutations: a review of the evidence.
Onco Targets Ther. 2016 Sep 6;9:5461-73. doi: 10.2147/OTT.S94745. eCollection 2016.
6
Epidermal growth factor receptor tyrosine kinase inhibitors in early-stage nonsmall cell lung cancer.
Curr Opin Oncol. 2015 Mar;27(2):102-7. doi: 10.1097/CCO.0000000000000163.
7
Adjuvant Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors (TKIs) in Resected Non-Small Cell Lung Cancer (NSCLC): A Systematic Review and Meta-analysis.
Am J Clin Oncol. 2019 May;42(5):440-445. doi: 10.1097/COC.0000000000000533.
8
Expression of insulin-like growth factor 1 receptor (IGF-1R) predicts poor responses to epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors in non-small cell lung cancer patients harboring activating EGFR mutations.
Lung Cancer. 2015 Mar;87(3):311-7. doi: 10.1016/j.lungcan.2015.01.004. Epub 2015 Jan 14.
9
Optimizing the sequencing of tyrosine kinase inhibitors (TKIs) in epidermal growth factor receptor (EGFR) mutation-positive non-small cell lung cancer (NSCLC).
Lung Cancer. 2019 Nov;137:113-122. doi: 10.1016/j.lungcan.2019.09.017. Epub 2019 Sep 23.
10
EGFR-TKIs in adjuvant treatment of lung cancer: to give or not to give?
Onco Targets Ther. 2015 Oct 13;8:2915-21. doi: 10.2147/OTT.S91627. eCollection 2015.
引用本文的文献
1
Perioperative Strategies in Resectable Non-Squamous Non-Small Cell Lung Cancer with EGFR Mutations and ALK Rearrangement.
Cancers (Basel). 2025 May 31;17(11):1844. doi: 10.3390/cancers17111844.
2
Effect of CYP3A4 inhibitor and induction on the pharmacokinetics and safety of FHND9041, a novel EGFR T790M inhibitor, in healthy Chinese.
BMC Pharmacol Toxicol. 2025 May 7;26(1):97. doi: 10.1186/s40360-025-00930-2.
3
Itraconazole Reversing Acquired Resistance to Osimertinib in NSCLC by Inhibiting the SHH/DUSP13B/p-STAT3 Axis.
Adv Sci (Weinh). 2025 Feb;12(7):e2409416. doi: 10.1002/advs.202409416. Epub 2024 Dec 25.
4
Management of Non-Metastatic Non-Small Cell Lung Cancer (NSCLC) with Driver Gene Alterations: An Evolving Scenario.
Curr Oncol. 2024 Aug 30;31(9):5121-5139. doi: 10.3390/curroncol31090379.
5
Traditional Chinese medicine combined with chemotherapy in the treatment of advanced non-small cell lung cancer: key drug screening and mechanism analysis.
Naunyn Schmiedebergs Arch Pharmacol. 2025 Jan;398(1):843-854. doi: 10.1007/s00210-024-03310-5. Epub 2024 Jul 29.
6
Status Assessment for Better Care of Early Stage Non-Small Cell Lung Carcinoma: What Is Changing in the Daily Practice of Pathologists?
Cells. 2021 Aug 21;10(8):2157. doi: 10.3390/cells10082157.
7
First-line treatment selection with organoids of an m + m stage IA1 patient with early metastatic recurrence after radical surgery and follow-up.
J Thorac Dis. 2020 Jul;12(7):3764-3773. doi: 10.21037/jtd-20-1882.
本文引用的文献
1
Society for Translational Medicine consensus on postoperative management of EGFR-mutant lung cancer (2019 edition).
Transl Lung Cancer Res. 2019 Dec;8(6):1163-1173. doi: 10.21037/tlcr.2019.12.14.
2
Overall Survival with Osimertinib in Untreated, -Mutated Advanced NSCLC.
N Engl J Med. 2020 Jan 2;382(1):41-50. doi: 10.1056/NEJMoa1913662. Epub 2019 Nov 21.
3
Erlotinib Versus Gemcitabine Plus Cisplatin as Neoadjuvant Treatment of Stage IIIA-N2 -Mutant Non-Small-Cell Lung Cancer (EMERGING-CTONG 1103): A Randomized Phase II Study.
J Clin Oncol. 2019 Sep 1;37(25):2235-2245. doi: 10.1200/JCO.19.00075. Epub 2019 Jun 13.
4
Adjuvant therapy with imatinib in gastrointestinal stromal tumors (GISTs)-review and perspectives.
Transl Gastroenterol Hepatol. 2019 Apr 9;4:24. doi: 10.21037/tgh.2019.03.07. eCollection 2019.
5
Adjuvant Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors (TKIs) in Resected Non-Small Cell Lung Cancer (NSCLC): A Systematic Review and Meta-analysis.
Am J Clin Oncol. 2019 May;42(5):440-445. doi: 10.1097/COC.0000000000000533.
6
The optimal duration of adjuvant endocrine therapy in early luminal breast cancer: A concise review.
Cancer Treat Rev. 2019 Mar;74:29-34. doi: 10.1016/j.ctrv.2019.01.007. Epub 2019 Jan 25.
7
SELECT: A Phase II Trial of Adjuvant Erlotinib in Patients With Resected Epidermal Growth Factor Receptor-Mutant Non-Small-Cell Lung Cancer.
J Clin Oncol. 2019 Jan 10;37(2):97-104. doi: 10.1200/JCO.18.00131. Epub 2018 Nov 16.
8
Erlotinib versus vinorelbine plus cisplatin as adjuvant therapy in Chinese patients with stage IIIA EGFR mutation-positive non-small-cell lung cancer (EVAN): a randomised, open-label, phase 2 trial.
Lancet Respir Med. 2018 Nov;6(11):863-873. doi: 10.1016/S2213-2600(18)30277-7. Epub 2018 Aug 24.
9
ADAURA: Phase III, Double-blind, Randomized Study of Osimertinib Versus Placebo in EGFR Mutation-positive Early-stage NSCLC After Complete Surgical Resection.
Clin Lung Cancer. 2018 Jul;19(4):e533-e536. doi: 10.1016/j.cllc.2018.04.004. Epub 2018 May 1.
10
Gefitinib versus vinorelbine plus cisplatin as adjuvant treatment for stage II-IIIA (N1-N2) EGFR-mutant NSCLC (ADJUVANT/CTONG1104): a randomised, open-label, phase 3 study.
Lancet Oncol. 2018 Jan;19(1):139-148. doi: 10.1016/S1470-2045(17)30729-5. Epub 2017 Nov 21.
Zotero 插件